secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001213900-24-000296
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea shareholders approve classified board, supermajority vote, eliminate written consent
--------------------------------------------------------------------------------

- Stockholders approved classifying Board into three classes with staggered 3-year terms; removal only for cause.
- Approved elimination of stockholder ability to act by written consent and to call special meetings.
- Approved requirement of 66 2/3% vote to amend Bylaws; vote results: 10,473,072 for, 1,513,065 against.
- Certificate restated to include officer exculpation and other governance changes; effective Dec 29, 2023.
- Clerical filing corrected reverse stock split (1:20) to be an amendment to the Restated Certificate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/0001213900-24-000296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-000296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer